Type your tag names separated by a space and hit enter

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Abstract

Corticorelin is a synthetic analog of the naturally occurring human peptide corticotropin-releasing factor (CRF). Several studies have indicated the ability of CRF to reduce the brain edema caused by brain tumors. Peritumoral brain edema (PBE), caused by an intracerebral tumor, manifests several features of vasogenic edema, which is a type of edema characterized by disruption of the blood-brain barrier. Traditionally, PBE has been treated using corticosteroids, primarily dexamethasone. Introduced more than four decades ago, dexamethasone revolutionized the treatment of PBE, but the side effects and withdrawal symptoms associated with corticosteroids propelled the investigation of other drugs. Clinical trials with the synthetic human CRF (hCRF) corticorelin (Xerecept, NEU-3002; Celtic Pharmaceutical Holdings) have indicated that this drug has a distinct advantage over classical corticosteroids in the treatment of PBE. Fewer and/or milder side effects have been reported for corticorelin compared with dexamethasone, although at higher doses of corticorelin several side effects, including hypotension and transient flushing, have been reported. Nevertheless, corticorelin was reasonably well tolerated in patients and healthy volunteers, and may be a good candidate for reducing PBE and associated neural damage, as well as improving neurological symptoms.

Links

Authors+Show Affiliations

US Department of Agriculture, Beltsville Human Nutrition Research Center, Diet, Genomics & Immunology Laboratory, Building 307C, Beltsville, MD 20705, USA. kiran.panickar@ars.usda.gov

Source

MeSH

Arthritis, Rheumatoid
Asthma
Brain Edema
Brain Neoplasms
Clinical Trials as Topic
Corticotropin-Releasing Hormone
Flushing
Humans
Hypotension
Treatment Outcome

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21154169

Citation

Panickar, Kiran S.. "Corticorelin, a Synthetic Human Corticotropin-releasing Factor Analog, for the Treatment of Peritumoral Brain Edema." Current Opinion in Molecular Therapeutics, vol. 12, no. 6, 2010, pp. 780-9.
Panickar KS. Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema. Curr Opin Mol Ther. 2010;12(6):780-9.
Panickar, K. S. (2010). Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema. Current Opinion in Molecular Therapeutics, 12(6), pp. 780-9.
Panickar KS. Corticorelin, a Synthetic Human Corticotropin-releasing Factor Analog, for the Treatment of Peritumoral Brain Edema. Curr Opin Mol Ther. 2010;12(6):780-9. PubMed PMID: 21154169.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema. A1 - Panickar,Kiran S, PY - 2010/12/15/entrez PY - 2010/12/15/pubmed PY - 2011/5/20/medline SP - 780 EP - 9 JF - Current opinion in molecular therapeutics JO - Curr. Opin. Mol. Ther. VL - 12 IS - 6 N2 - Corticorelin is a synthetic analog of the naturally occurring human peptide corticotropin-releasing factor (CRF). Several studies have indicated the ability of CRF to reduce the brain edema caused by brain tumors. Peritumoral brain edema (PBE), caused by an intracerebral tumor, manifests several features of vasogenic edema, which is a type of edema characterized by disruption of the blood-brain barrier. Traditionally, PBE has been treated using corticosteroids, primarily dexamethasone. Introduced more than four decades ago, dexamethasone revolutionized the treatment of PBE, but the side effects and withdrawal symptoms associated with corticosteroids propelled the investigation of other drugs. Clinical trials with the synthetic human CRF (hCRF) corticorelin (Xerecept, NEU-3002; Celtic Pharmaceutical Holdings) have indicated that this drug has a distinct advantage over classical corticosteroids in the treatment of PBE. Fewer and/or milder side effects have been reported for corticorelin compared with dexamethasone, although at higher doses of corticorelin several side effects, including hypotension and transient flushing, have been reported. Nevertheless, corticorelin was reasonably well tolerated in patients and healthy volunteers, and may be a good candidate for reducing PBE and associated neural damage, as well as improving neurological symptoms. SN - 2040-3445 UR - https://www.unboundmedicine.com/medline/citation/21154169/Corticorelin,_a_synthetic_human_corticotropin-releasing_factor_analog,_for_the_treatment_of_peritumoral_brain_edema L2 - http://www.diseaseinfosearch.org/result/2473 DB - PRIME DP - Unbound Medicine ER -